New Adult Preventative Vaccine Approved for RSV
Available for Adults 60 Years and Older
CORPUS CHRISTI, TX – The United States Food and Drug Administration (FDA) has approved two vaccines for the prevention of Respiratory Syncytial Virus (RSV). The vaccines are for adults ages 60 years and older and are now available at local pharmacies in Corpus Christi.
The two RSV vaccines, Arexvy by GlaxoSmithKline (GSK) and Abrysvo by Pfizer, cause an immune response that can protect individuals from respiratory illness if infected with RSV in the future. Both vaccines are given as a single dose. Adults aged 60 years and older should consult with their healthcare provider to determine whether the RSV vaccination is right for them. If an individual has had RSV in the past, the RSV vaccination can help prevent future respiratory illness from RSV. Early vaccination will ensure individuals are protected by the time RSV begins to circulate in the community.
In the United States, RSV causes seasonal epidemics of respiratory illness during the fall and winter months. RSV is an RNA virus, and transmission occurs primarily via respiratory droplets when a person coughs or sneezes or through direct contact with a contaminated surface. Each season, RSV causes substantial morbidity and mortality in infants, young children, and older adults.
Most adult RSV cases occur among older adults, with an estimated 60,000-160,000 hospitalizations and 6,000-10,000 deaths annually. Adults who have chronic obstructive pulmonary disease, asthma, congestive heart failure, coronary artery disease, cerebrovascular disease, diabetes mellitus, and chronic kidney disease are at increased risk for RSV.
For more information, media representatives can contact Public Information Officer Brittany Claramunt at 361-826-7232 or by email at email@example.com.